2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC
  5. Traditional Cytotoxic Agents Isoform

Traditional Cytotoxic Agents

 

Traditional Cytotoxic Agents Related Products (28):

Cat. No. Product Name Effect Purity
  • HY-117410
    Vipivotide tetraxetan
    		Inhibitor 99.57%
    Vipivotide tetraxetan (PSMA-617) is a high potent prostate-specific membrane antigen (PSMA) inhibitor, with a Ki of 0.37 nM. Vipivotide tetraxetan (PSMA-617) is designed consisting of three components: the pharmacophore Glutamate-urea-Lysine, the chelator DOTA able to complex both 68Ga or 177Lu, and a linker connecting these two entities. Glutamate-urea-Lysine is the selective pharmacophore to bind to prostate specific membrane antigen.
  • HY-134723
    DBCO-PEG4-GGFG-Dxd
    		98.64%
    DBCO-PEG4-GGFG-Dxd is a agent-linker conjugate for ADC with potent antitumor activity by using Dxd (a DNA topoisomerase I inhibitor), linked via the cleavable ADC linker DBCO-PEG4-GGFG. DBCO-PEG4-GGFG-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
  • HY-128870
    Mal-PEG2-VCP-Eribulin
    		99.82%
    Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin (HY-13442). Eribulin is a mechanistically unique microtubule inhibitor and Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Mal-PEG2-VCP-Eribulin is an Eribulin-based agent for antibody conjugates.
  • HY-133433
    DBCO-PEG4-VA-PBD
    DBCO-PEG4-VA-PBD is a agent-linker conjugate for ADC by using the antitumor antibiotic, Pyrrolobenzodiazepine (PBD), linked via DBCO-PEG4-VA. DBCO-PEG4-VA-PBD is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
  • HY-128903
    MC-Val-Cit-PAB-carfilzomib iodide
    MC-Val-Cit-PAB-carfilzomib iodide is a agent-linker conjugate for ADC with potent antitumor activity by using carfilzomib (an irreversible proteasome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
  • HY-128897
    MC-VC-PABC-DNA31
    		98.71%
    MC-VC-PABC-DNA31 is a agent-linker conjugate for ADC with potent antitumor activity by using DNA31 (a potent RNA polymerase inhibitor), linked via the ADC linker MC-VC-PABC.
  • HY-128902
    MC-Val-Cit-PAB-vinblastine
    MC-Val-Cit-PAB-vinblastine is a agent-linker conjugate for ADC with potent antitumor activity by using vinblastine (an microtubule protein inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
  • HY-112615
    NAMPT inhibitor-linker 1
    		98.08%
    NAMPT inhibitor-linker 1 is a agent-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. ADC-3 consists of an NAMPT inhibitor-linker 1 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526 cells, with IC50s of <3 pM and 9 pM, respectively.
  • HY-112616
    NAMPT inhibitor-linker 2
    		98.11%
    NAMPT inhibitor-linker 2 is a agent-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. ADC-4 consists of an NAMPT inhibitor-linker 2 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526, with IC50s of <7 pM and 40 pM, respectively.
  • HY-141536
    PSMA-ALB-56
    		98.92%
    PSMA-ALB-56 is a PSMA-targeting radioligand designed by combining the glutamate-urea PSMA-binding entity and an albumin binder.
  • HY-136297
    DGN549-C
    DGN549-C consists a cleavable ADC linker valine-alanine (va) and PBD dimer. DGN549 is a novel DNA-alkylating cytotoxic payload and can be used in the synthesis of antibody-agent conjugates (ADCs).
  • HY-128909
    MC-Val-Cit-PAB-rifabutin
    MC-Val-Cit-PAB-rifabutin is a agent-linker conjugate for ADC with potent antitumor activity by using rifabutin (an DNA-dependent RNA polymerase inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
  • HY-128906
    MC-Val-Cit-PAB-Retapamulin
    		99.00%
    MC-Val-Cit-PAB-Retapamulin is a agent-linker conjugate for ADC with potent antitumor activity by using Retapamulin (a ribosome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
  • HY-128908
    MC-Val-Cit-PAB-Indibulin
    MC-Val-Cit-PAB-Indibulin is a agent-linker conjugate for ADC with potent antitumor activity by using Indibulin (an orally applicable inhibitor of tubulin assembly), linked via the ADC linker MC-Val-Cit-PAB.
  • HY-128907
    MC-Val-Cit-PAB-clindamycin
    		99.99%
    MC-Val-Cit-PAB-clindamycin is a agent-linker conjugate for ADC with potent antitumor activity by using clindamycin (a protein synthesis inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
  • HY-114325
    AcLysValCit-PABC-DMAE-SW-163D
    AcLysValCit-PABC-DMAE-SW-163D is a agent-linker conjugates for ADC which consists of a natural bis-intercalator, SW-163D, conjugated via an AcLysValCitPABC-DMAE linker.
  • HY-139018
    TLR7/8 agonist 4 hydroxy-PEG10-acid
    TLR7/8 agonist 4 hydroxy-PEG10-acid (compound 9) is a agent-linker conjugate for ADC with potent antitumor activity by using TLR7/8 agonist 4 (HY-139018; a TLR7/8 agonist), linked via the cleavable ADC linker hydroxy-PEG10-acid (HY-133307).
  • HY-128871
    VCP-Eribulin
    VCP-Eribulin consists the ADCs linker (VCP) and Eribulin. Eribulin is a mechanistically unique microtubule inhibitor for cancer. VCP-Eribulin is an Eribulin-based agent for antibody conjugates.
  • HY-112806
    ST8155AA1
    ST8155AA1 is a part of antibody agent conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity.
  • HY-139018A
    TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride
    TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride (compound 9) is a agent-linker conjugate for ADC with potent antitumor activity by using TLR7/8 agonist 4 (HY-139018; a TLR7/8 agonist), linked via the cleavable ADC linker hydroxy-PEG10-acid (HY-133307).